Factors affecting the accuracy of anti‐BRAF V600E immunohistochemistry results in ameloblastomas
Background There are still some controversies about the results of anti‐BRAF V600E‐specific antibody immunohistochemistry in ameloblastomas. This study aimed to examine the accuracy of V600E‐specific antibody immunohistochemistry in detection of BRAF V600E mutation in ameloblastoma tissue sections o...
Gespeichert in:
| Veröffentlicht in: | Journal of oral pathology & medicine 2023-04, Vol.52 (4), p.342-350 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 350 |
|---|---|
| container_issue | 4 |
| container_start_page | 342 |
| container_title | Journal of oral pathology & medicine |
| container_volume | 52 |
| creator | Chang, Julia Yu Fong Lu, Pei Hsuan Tseng, Chih‐Huang Wang, Yi‐Ping Lee, Jang‐Jaer Chiang, Chun‐Pin |
| description | Background
There are still some controversies about the results of anti‐BRAF V600E‐specific antibody immunohistochemistry in ameloblastomas. This study aimed to examine the accuracy of V600E‐specific antibody immunohistochemistry in detection of BRAF V600E mutation in ameloblastoma tissue sections of different ages.
Methods
The BRAF V600E status of 64 ameloblastoma specimens was assessed using both Sanger sequencing and V600E‐specific antibody immunohistochemistry, and the sensitivity, specificity, positive predictive value, and negative predictive value were calculated. The difference in V600E‐specific antibody immunohistochemistry staining intensity among the three groups of ameloblastoma tissue blocks of different ages was evaluated by chi‐square test. The consistency between V600E‐specific antibody immunohistochemistry and DNA sequencing results and the V600E‐specific antibody immunohistochemistry staining intensity of 15 paired newly‐cut and 3‐month storage sections of the same 15 ameloblastomas were also compared.
Results
For detection of BRAF V600E mutation, the V600E‐specific antibody immunohistochemistry had high sensitivity (98.21% 55/56), specificity (87.5% 7/8), positive predictive value (98.21% 55/56), and negative predictive value (87.5% 7/8). Heterogeneity of the staining intensity was observed in the same tissue section, but all or none expression pattern was noticed in the solid tumor nests. The storage time of paraffin tissue blocks ranging from 2 to 14 years did not affect the V600E‐specific antibody‐positive staining intensity. However, the three‐month storage sections showed a significant diminishment of V600E‐specific antibody‐positive staining signals.
Conclusions
The BRAF V600E‐specific antibody immunohistochemistry is suitable for routine detection of BRAF V600E mutation in ameloblastomas. The all or none expression pattern suggests the BRAF V600E mutation may be an early event in the pathogenesis of ameloblastoma. |
| doi_str_mv | 10.1111/jop.13399 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2763334509</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2794941347</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3539-5016fa92d01c5098b8030e301ad11debc4e960dd2eeb9f955d6cbb50396bfa153</originalsourceid><addsrcrecordid>eNp1kMtOwzAQRS0EgvJY8APIEhtYpIxjO8VLQJSHkEAI2Ea2M6GpkrjYiVB3fALfyJdgaGGBxGzuYs4cjS4huwyGLM7R1M2GjHOlVsiAZQAJjJhYJQNQIJJUsnSDbIYwBWAjLtg62eBZlkqh1ICYsbad84HqskTbVe0z7SZItbW913ZOXUl121Ufb--n9ydj-hTt57Rqmr51kyp0zk6wienn1GPo6y7QqqW6wdqZWsd9o8M2WSt1HXBnmVvkcXz-cHaZ3NxeXJ2d3CSWS64SCSwrtUoLYFaCOjbHwAE5MF0wVqCxAlUGRZEiGlUqKYvMGiOBq8yUmkm-RQ4W3pl3Lz2GLo-fWaxr3aLrQ56OMs65iO6I7v9Bp673bfwuUkoowbgYRepwQVnvQvBY5jNfNdrPcwb5V_HxapZ_Fx_ZvaWxNw0Wv-RP0xE4WgCvVY3z_0359e3dQvkJGP6NjQ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2794941347</pqid></control><display><type>article</type><title>Factors affecting the accuracy of anti‐BRAF V600E immunohistochemistry results in ameloblastomas</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>Chang, Julia Yu Fong ; Lu, Pei Hsuan ; Tseng, Chih‐Huang ; Wang, Yi‐Ping ; Lee, Jang‐Jaer ; Chiang, Chun‐Pin</creator><creatorcontrib>Chang, Julia Yu Fong ; Lu, Pei Hsuan ; Tseng, Chih‐Huang ; Wang, Yi‐Ping ; Lee, Jang‐Jaer ; Chiang, Chun‐Pin</creatorcontrib><description>Background
There are still some controversies about the results of anti‐BRAF V600E‐specific antibody immunohistochemistry in ameloblastomas. This study aimed to examine the accuracy of V600E‐specific antibody immunohistochemistry in detection of BRAF V600E mutation in ameloblastoma tissue sections of different ages.
Methods
The BRAF V600E status of 64 ameloblastoma specimens was assessed using both Sanger sequencing and V600E‐specific antibody immunohistochemistry, and the sensitivity, specificity, positive predictive value, and negative predictive value were calculated. The difference in V600E‐specific antibody immunohistochemistry staining intensity among the three groups of ameloblastoma tissue blocks of different ages was evaluated by chi‐square test. The consistency between V600E‐specific antibody immunohistochemistry and DNA sequencing results and the V600E‐specific antibody immunohistochemistry staining intensity of 15 paired newly‐cut and 3‐month storage sections of the same 15 ameloblastomas were also compared.
Results
For detection of BRAF V600E mutation, the V600E‐specific antibody immunohistochemistry had high sensitivity (98.21% 55/56), specificity (87.5% 7/8), positive predictive value (98.21% 55/56), and negative predictive value (87.5% 7/8). Heterogeneity of the staining intensity was observed in the same tissue section, but all or none expression pattern was noticed in the solid tumor nests. The storage time of paraffin tissue blocks ranging from 2 to 14 years did not affect the V600E‐specific antibody‐positive staining intensity. However, the three‐month storage sections showed a significant diminishment of V600E‐specific antibody‐positive staining signals.
Conclusions
The BRAF V600E‐specific antibody immunohistochemistry is suitable for routine detection of BRAF V600E mutation in ameloblastomas. The all or none expression pattern suggests the BRAF V600E mutation may be an early event in the pathogenesis of ameloblastoma.</description><identifier>ISSN: 0904-2512</identifier><identifier>EISSN: 1600-0714</identifier><identifier>DOI: 10.1111/jop.13399</identifier><identifier>PMID: 36625499</identifier><language>eng</language><publisher>Denmark: Wiley Subscription Services, Inc</publisher><subject>Ameloblastoma ; Ameloblastoma - diagnosis ; Ameloblastoma - genetics ; Ameloblastoma - pathology ; Antibodies ; Biomarkers, Tumor - genetics ; BRAF V600E immunohistochemistry ; Chi-Square Distribution ; DNA sequencing ; Humans ; Immunohistochemistry ; Mutation ; Nests ; Paraffin ; Proto-Oncogene Proteins B-raf - genetics ; Solid tumors</subject><ispartof>Journal of oral pathology & medicine, 2023-04, Vol.52 (4), p.342-350</ispartof><rights>2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3539-5016fa92d01c5098b8030e301ad11debc4e960dd2eeb9f955d6cbb50396bfa153</citedby><cites>FETCH-LOGICAL-c3539-5016fa92d01c5098b8030e301ad11debc4e960dd2eeb9f955d6cbb50396bfa153</cites><orcidid>0000-0002-6190-7162 ; 0000-0001-9574-2194 ; 0000-0002-3880-3787</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fjop.13399$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fjop.13399$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36625499$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chang, Julia Yu Fong</creatorcontrib><creatorcontrib>Lu, Pei Hsuan</creatorcontrib><creatorcontrib>Tseng, Chih‐Huang</creatorcontrib><creatorcontrib>Wang, Yi‐Ping</creatorcontrib><creatorcontrib>Lee, Jang‐Jaer</creatorcontrib><creatorcontrib>Chiang, Chun‐Pin</creatorcontrib><title>Factors affecting the accuracy of anti‐BRAF V600E immunohistochemistry results in ameloblastomas</title><title>Journal of oral pathology & medicine</title><addtitle>J Oral Pathol Med</addtitle><description>Background
There are still some controversies about the results of anti‐BRAF V600E‐specific antibody immunohistochemistry in ameloblastomas. This study aimed to examine the accuracy of V600E‐specific antibody immunohistochemistry in detection of BRAF V600E mutation in ameloblastoma tissue sections of different ages.
Methods
The BRAF V600E status of 64 ameloblastoma specimens was assessed using both Sanger sequencing and V600E‐specific antibody immunohistochemistry, and the sensitivity, specificity, positive predictive value, and negative predictive value were calculated. The difference in V600E‐specific antibody immunohistochemistry staining intensity among the three groups of ameloblastoma tissue blocks of different ages was evaluated by chi‐square test. The consistency between V600E‐specific antibody immunohistochemistry and DNA sequencing results and the V600E‐specific antibody immunohistochemistry staining intensity of 15 paired newly‐cut and 3‐month storage sections of the same 15 ameloblastomas were also compared.
Results
For detection of BRAF V600E mutation, the V600E‐specific antibody immunohistochemistry had high sensitivity (98.21% 55/56), specificity (87.5% 7/8), positive predictive value (98.21% 55/56), and negative predictive value (87.5% 7/8). Heterogeneity of the staining intensity was observed in the same tissue section, but all or none expression pattern was noticed in the solid tumor nests. The storage time of paraffin tissue blocks ranging from 2 to 14 years did not affect the V600E‐specific antibody‐positive staining intensity. However, the three‐month storage sections showed a significant diminishment of V600E‐specific antibody‐positive staining signals.
Conclusions
The BRAF V600E‐specific antibody immunohistochemistry is suitable for routine detection of BRAF V600E mutation in ameloblastomas. The all or none expression pattern suggests the BRAF V600E mutation may be an early event in the pathogenesis of ameloblastoma.</description><subject>Ameloblastoma</subject><subject>Ameloblastoma - diagnosis</subject><subject>Ameloblastoma - genetics</subject><subject>Ameloblastoma - pathology</subject><subject>Antibodies</subject><subject>Biomarkers, Tumor - genetics</subject><subject>BRAF V600E immunohistochemistry</subject><subject>Chi-Square Distribution</subject><subject>DNA sequencing</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Mutation</subject><subject>Nests</subject><subject>Paraffin</subject><subject>Proto-Oncogene Proteins B-raf - genetics</subject><subject>Solid tumors</subject><issn>0904-2512</issn><issn>1600-0714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kMtOwzAQRS0EgvJY8APIEhtYpIxjO8VLQJSHkEAI2Ea2M6GpkrjYiVB3fALfyJdgaGGBxGzuYs4cjS4huwyGLM7R1M2GjHOlVsiAZQAJjJhYJQNQIJJUsnSDbIYwBWAjLtg62eBZlkqh1ICYsbad84HqskTbVe0z7SZItbW913ZOXUl121Ufb--n9ydj-hTt57Rqmr51kyp0zk6wienn1GPo6y7QqqW6wdqZWsd9o8M2WSt1HXBnmVvkcXz-cHaZ3NxeXJ2d3CSWS64SCSwrtUoLYFaCOjbHwAE5MF0wVqCxAlUGRZEiGlUqKYvMGiOBq8yUmkm-RQ4W3pl3Lz2GLo-fWaxr3aLrQ56OMs65iO6I7v9Bp673bfwuUkoowbgYRepwQVnvQvBY5jNfNdrPcwb5V_HxapZ_Fx_ZvaWxNw0Wv-RP0xE4WgCvVY3z_0359e3dQvkJGP6NjQ</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Chang, Julia Yu Fong</creator><creator>Lu, Pei Hsuan</creator><creator>Tseng, Chih‐Huang</creator><creator>Wang, Yi‐Ping</creator><creator>Lee, Jang‐Jaer</creator><creator>Chiang, Chun‐Pin</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6190-7162</orcidid><orcidid>https://orcid.org/0000-0001-9574-2194</orcidid><orcidid>https://orcid.org/0000-0002-3880-3787</orcidid></search><sort><creationdate>202304</creationdate><title>Factors affecting the accuracy of anti‐BRAF V600E immunohistochemistry results in ameloblastomas</title><author>Chang, Julia Yu Fong ; Lu, Pei Hsuan ; Tseng, Chih‐Huang ; Wang, Yi‐Ping ; Lee, Jang‐Jaer ; Chiang, Chun‐Pin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3539-5016fa92d01c5098b8030e301ad11debc4e960dd2eeb9f955d6cbb50396bfa153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Ameloblastoma</topic><topic>Ameloblastoma - diagnosis</topic><topic>Ameloblastoma - genetics</topic><topic>Ameloblastoma - pathology</topic><topic>Antibodies</topic><topic>Biomarkers, Tumor - genetics</topic><topic>BRAF V600E immunohistochemistry</topic><topic>Chi-Square Distribution</topic><topic>DNA sequencing</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Mutation</topic><topic>Nests</topic><topic>Paraffin</topic><topic>Proto-Oncogene Proteins B-raf - genetics</topic><topic>Solid tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chang, Julia Yu Fong</creatorcontrib><creatorcontrib>Lu, Pei Hsuan</creatorcontrib><creatorcontrib>Tseng, Chih‐Huang</creatorcontrib><creatorcontrib>Wang, Yi‐Ping</creatorcontrib><creatorcontrib>Lee, Jang‐Jaer</creatorcontrib><creatorcontrib>Chiang, Chun‐Pin</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of oral pathology & medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chang, Julia Yu Fong</au><au>Lu, Pei Hsuan</au><au>Tseng, Chih‐Huang</au><au>Wang, Yi‐Ping</au><au>Lee, Jang‐Jaer</au><au>Chiang, Chun‐Pin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Factors affecting the accuracy of anti‐BRAF V600E immunohistochemistry results in ameloblastomas</atitle><jtitle>Journal of oral pathology & medicine</jtitle><addtitle>J Oral Pathol Med</addtitle><date>2023-04</date><risdate>2023</risdate><volume>52</volume><issue>4</issue><spage>342</spage><epage>350</epage><pages>342-350</pages><issn>0904-2512</issn><eissn>1600-0714</eissn><abstract>Background
There are still some controversies about the results of anti‐BRAF V600E‐specific antibody immunohistochemistry in ameloblastomas. This study aimed to examine the accuracy of V600E‐specific antibody immunohistochemistry in detection of BRAF V600E mutation in ameloblastoma tissue sections of different ages.
Methods
The BRAF V600E status of 64 ameloblastoma specimens was assessed using both Sanger sequencing and V600E‐specific antibody immunohistochemistry, and the sensitivity, specificity, positive predictive value, and negative predictive value were calculated. The difference in V600E‐specific antibody immunohistochemistry staining intensity among the three groups of ameloblastoma tissue blocks of different ages was evaluated by chi‐square test. The consistency between V600E‐specific antibody immunohistochemistry and DNA sequencing results and the V600E‐specific antibody immunohistochemistry staining intensity of 15 paired newly‐cut and 3‐month storage sections of the same 15 ameloblastomas were also compared.
Results
For detection of BRAF V600E mutation, the V600E‐specific antibody immunohistochemistry had high sensitivity (98.21% 55/56), specificity (87.5% 7/8), positive predictive value (98.21% 55/56), and negative predictive value (87.5% 7/8). Heterogeneity of the staining intensity was observed in the same tissue section, but all or none expression pattern was noticed in the solid tumor nests. The storage time of paraffin tissue blocks ranging from 2 to 14 years did not affect the V600E‐specific antibody‐positive staining intensity. However, the three‐month storage sections showed a significant diminishment of V600E‐specific antibody‐positive staining signals.
Conclusions
The BRAF V600E‐specific antibody immunohistochemistry is suitable for routine detection of BRAF V600E mutation in ameloblastomas. The all or none expression pattern suggests the BRAF V600E mutation may be an early event in the pathogenesis of ameloblastoma.</abstract><cop>Denmark</cop><pub>Wiley Subscription Services, Inc</pub><pmid>36625499</pmid><doi>10.1111/jop.13399</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-6190-7162</orcidid><orcidid>https://orcid.org/0000-0001-9574-2194</orcidid><orcidid>https://orcid.org/0000-0002-3880-3787</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0904-2512 |
| ispartof | Journal of oral pathology & medicine, 2023-04, Vol.52 (4), p.342-350 |
| issn | 0904-2512 1600-0714 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2763334509 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Ameloblastoma Ameloblastoma - diagnosis Ameloblastoma - genetics Ameloblastoma - pathology Antibodies Biomarkers, Tumor - genetics BRAF V600E immunohistochemistry Chi-Square Distribution DNA sequencing Humans Immunohistochemistry Mutation Nests Paraffin Proto-Oncogene Proteins B-raf - genetics Solid tumors |
| title | Factors affecting the accuracy of anti‐BRAF V600E immunohistochemistry results in ameloblastomas |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-21T23%3A13%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Factors%20affecting%20the%20accuracy%20of%20anti%E2%80%90BRAF%20V600E%20immunohistochemistry%20results%20in%20ameloblastomas&rft.jtitle=Journal%20of%20oral%20pathology%20&%20medicine&rft.au=Chang,%20Julia%20Yu%20Fong&rft.date=2023-04&rft.volume=52&rft.issue=4&rft.spage=342&rft.epage=350&rft.pages=342-350&rft.issn=0904-2512&rft.eissn=1600-0714&rft_id=info:doi/10.1111/jop.13399&rft_dat=%3Cproquest_cross%3E2794941347%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2794941347&rft_id=info:pmid/36625499&rfr_iscdi=true |